Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies

Daiichi Sankyo and AstraZeneca entered a clinical-trial collaboration with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) combined with ivonescimab across multiple solid-tumor types. The agreement expands clinical development of the oncology assets and could broaden their potential use, though no trial results, financial terms, or regulatory milestones were disclosed.